Indirubin-3′-monoxime

Additional information:
Indirubin-3′-monoxime is a potent GSK-3β inhibitor, and weakly inhibits 5-Lipoxygenase, with IC50s of 22 nM and 7.8-10 µM, respectively; Indirubin-3′-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC50s of 100 and 180 nM.|Product information|CAS Number: 160807-49-8|Molecular Weight: 277.28|Formula: C16H11N3O2|Synonym:|Indirubin-3′-oxime|Chemical Name: (E, 3E)-3-(hydroxyimino)-1′, 2′-dihydro-1H, 3H-[2, 3′-biindolyliden]-2′-one|Smiles: O/N=C1/C(/NC2=CC=CC=C2/1)=C1\C(=O)NC2=CC=CC=C2\1|InChiKey: HBDSHCUSXQATPO-OIXOFKMYSA-N|InChi: InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17,21H,(H,18,20)/b15-13+,19-14+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 37 mg/mL (133.44 mM)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Indirubin-3′-monoxime inhibits GSK-3β by competing with ATP, with Ki of 0.{{Rifapentine} web|{Rifapentine} Bacterial|{Rifapentine} Technical Information|{Rifapentine} Purity|{Rifapentine} custom synthesis|{Rifapentine} Autophagy} 85 μM, and Km of 110 μM.{{Florfenicol} MedChemExpress|{Florfenicol} Anti-infection|{Florfenicol} Purity & Documentation|{Florfenicol} In Vitro|{Florfenicol} custom synthesis|{Florfenicol} Epigenetics} Indirubin-3′-monoxime also inhibits tau phosphorylation by GSK-3β, with an IC50 value of around 100 nM. Indirubin-3′-monoxime completely inhibits the phosphorylation of the AT100 epitope. Indirubin-3′-monoxime inhibits vascular smooth muscle cell (VSMC) proliferation with IC50 of ∼2 µM. Indirubin-3′-monoxime blunts migration of VSMC stimulated with the PDGF. Indirubin-3′-monoxime interferes with the migratory response in VSMC, and also suppresses the production of pro-migratory LT in monocytes.PMID:33276090 Moreover, Indirubin-3′-monoxime inhibits 5-lipoxygenase (5-LO) product synthesis in monocytes and neutrophils, with the same potency (IC50=5.0±1.1 and 3.7±1.2 µM, respectively). Indirubin-3′-monoxime is an inhibitor of 5-LO, with IC50 of 7.8-10 µM in cell-free assay.|In Vivo:|Indirubin-3′-monoxime (0.1, 0.2 and 0.4 mg/kg, i.p) dose dependently reverses the cognitive impairment and combats the elevated oxidative stress markers in HFD fed mice. Indirubin-3′-monoxime also dose dependently lowers the serum glucose, TGs, TC and insulin levels, and improves the β-cell functioning in HFD fed mice. Moreover, Indirubin-3′-monoxime treatment significantly decreases HOMA-IR levels compared to HFD group. Indirubin-3′-monoxime (0.4 mg/kg) significantly attenuates the increased EL in the HFD group.|References:|Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60.Sharma S, et al. Neuroprotective role of Indirubin-3′-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):1009-15.Blazevic T, et al. Indirubin-3′-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32.Products are for research use only. Not for human use.|